Alan Ezekowitz bought $92k of SEPN
director at Septerna, Inc.. 13,319 shares at an average of $6.93, traded Mar 7, 2025, filed Mar 10, 2025.
Score components
- +15RoleDirector
- +9Trade size$92k at market
- +3Relative to holdingsHoldings up 13%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-036321, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 7, 2025 | POpen-market purchase Common Stock | +13,319 | $6.93 | $92k | 117,420 | Mar 10, 2025 |
Related signals
Other insiders at Septerna, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Septerna, Inc. | Daniel D. Long SVP, Drug Discovery | $126k 3,333 shares | -3% | |
| 51Moderate | Septerna, Inc. | Alan Ezekowitz director | $516k 86,681 shares | +498% | |
| 43Moderate | Septerna, Inc. | Jeffrey Finer CEO and President | $97k 17,000 shares | +2% | |
| 58Moderate | Septerna, Inc. | Ra Capital Management, L.p. director, owner | $75M 4,170,000 shares | +246% | |
| 43Moderate | Septerna, Inc. | Third Rock Ventures V, L.P. owner | $12M 650,000 shares | +11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.